Customized phage therapies to eradicate
harmful bacteria in chronic diseases

Our phage therapy development and target discovery technologies were developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science
Learn about our technology

BiomX’s founders, management and investors all have a long history of excellence that is propelling us to continued success and innovation
Learn about our leadership team

BiomX News

BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update

– Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020
– On track for Phase 2 cosmetic clinical study of BX001 in acne first quarter of 2021
– Cash and equivalents of $70.6 million expected to fund current operating plan through mid-2022
– Company to host conference call today at 8:00 a.m. Eastern Time